«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

30卷

期数:

2024年05期

页码:

385-390

栏目:

肿瘤疾病专题

出版日期:

2024-09-25

文章信息/Info

Title:

The expression and prognostic value of ras-association domain family 10 in non-small cell lung cancer

文章编号:

1006-8147（2024）05-0385-06

作者:

张静怡¹; 2; 迟航³; 杨鑫¹; 汪玉龙¹; 赵伟鹏¹

（1.天津医科大学肿瘤医院，国家恶性肿瘤临床医学研究中心，天津市恶性肿瘤临床医学研究中心，天津市肿瘤防治重点实验室，天津 300060；2. 天津市中西医结合医院肿瘤内科，天津300102；3. 天津市中西医结合医院呼吸内科，天津 300102）

Author(s):

ZHANG Jingyi¹; 2; CHI Hang³; YANG Xin¹; WANG Yulong¹; ZHAO Weipeng¹

关键词:

非小细胞肺癌; RASSF10; 甲基化; 预后

Keywords:

non-small cell lung cancer;  RASSF10; methylation;  prognosis

分类号:

R734.2

DOI:

10.20135/j.issn.1006-8147.2024.05.0385

文献标志码:

A

摘要:

目的：探讨ras-相关结构域家族（ras-association domain family，RASSF）10在非小细胞肺癌中的表达，分析其与非小细胞肺癌临床病理特征和预后的关系。方法：采用qRT-PCR和Western 印迹检测RASSF10 mRNA和蛋白的表达；甲基化特异性聚合酶链式反应（MSP）检测RASSF10启动子甲基化状态，采用免疫组化和酶联免疫吸附测定法（ELISA）检测石蜡组织和血液中RASSF10蛋白表达，Cox回归模型进行生存分析。结果：在非小细胞肺癌细胞株SPCA-1中 RASSF10 mRNA及蛋白（z=21.38、33.14，均P＜0.05）、在NCI-H157中RASSF10 mRNA及蛋白（z=56.73、56.34，均P＜0.05）均低于非肿瘤细胞株。MSP发现RASSF10在SPCA-1和NCI-H157细胞株启动子区甲基化，用5-氮杂-2′-脱氧胞苷处理后，RASSF10在SPCA-1和NCI-H157细胞株中mRNA和蛋白（t=18.14、56.13，均P＜0.05）的表达增加。RASSF10启动子甲基化状态与组织中和血清中RASSF10的低表达密切相关（χ2 =19.271、4.831，均P<0.05）。预后多因素分析石蜡组织中RASSF10表达（HR=0.508，P<0.05）和N分期（HR=1.839，P<0.001）为非小细胞肺癌患者预后独立因素，RASSF10表达与肿瘤直径（χ2 =4.787，P＜0.05）、气道内播散（χ2 =15.618，P<0.001）和N分期（χ2 =11.588，P＜0.01）密切相关。结论：RASSF10在非小细胞肺癌中表达降低，与非小细胞肺癌肿瘤进展密切相关，是非小细胞肺癌早期诊断及预后有价值的肿瘤标志物。

Abstract:

Objective：To investigate the expression and methylation status of ras-association domain family（RASSF）10 and its correlation with the clinicopathological characteristics and prognosis in non-small cell lung cancer. Methods：The expression of RASSF10 were detected by real-time quantitative reverse transcription PCR and Western blotting. Methylation-specific PCR（MSP） analysis was utilized to detect the methylation status of the RASSF10 promoter. RASSF10 was analyzed by immunohistochemistry and enzyme-linked Immunosorbent Assay（ELISA）. Overall survival was subjected to multivariate analysis by using Cox proportional hazard model. Results：The mRNA SPCA-1（z=21.38，P＜0.05），NCI-H157（z=56.73，P＜0.05） and protein expression levels SPCA-1（z=33.14，P＜0.01），NCI-H157（z=56.34，P＜0.01） of RASSF10 in non-small cell lung cancer cell lines（SPCA-1和NCI-H157） were lower than those in non-tumor cell line. RASSF10 was methylated in SPCA-1 and NCI-H157 cell lines，after treatment with 5-aza-2′-deoxycytidine，RASSF10 expression was increased in the mRNA（t=18.14，P＜0.05） and protein expression levels（t=56.13，P＜0.05） cell lines by MSP. The methylation status of the RASSF10 promoter was intimately and significantly correlated with RASSF10 expression in tumor and blood（χ2=19.271，4.831，both P<0.05）. The methylation status of the RASSF10 promoter and RASSF10 expression were associated with the survival of patients with non-small cell lung cancer . The RASSF10 expression（HR=0.508，P<0.05） and lymph node stage（HR=1.839，P<0.001） were identified as the an independent predictor of the overall survival. Size of tumor（χ2=4.787，P<0.05），intratracheal dissemination（χ2=15.618，P<0.001） and lymph node stage（χ2=11.588，P<0.01） were related with RASSF10 expression. Conclusion：The expression of RASSF10 is low in non-small cell lung cancer. RASSF10 in tissues may be a valuable biomarker for the assessment of non-small cell lung cancer prognosis.

参考文献/References:

[1] LEE J H，SAXENA A，GIACCONE G. Advancements in small cell lung cancer[J]. Semin Cancer Biol，2023，93（8）：123-128.
[2] PIRKER R. Treatment of advanced non-small-cell lung cancer：from chemotherapy to chemoimmunotherapy[J]. J Oncol Pract，2018， 14（9）：537-538.
[3] CYRIAC G，GANDHI L. Emerging biomarkers for immune checkpoint inhibition in lung cancer[J]. Semin Cancer Biol，2018，52（2）：269-277.
[4] AROOQI A A，KAPANOVA G，KUSSAINOV A Z，et al. Regulation of RASSF by non-coding RNAs in different cancers：RASSFs as masterminds of their own destiny as tumor suppressors and oncogenes[J]. Noncoding RNA Res，2022，7（2）：123-131.
[5] LU D，MA J，ZHAN Q，et al. Epigenetic silencing of RASSF10 promotes tumor growth in esophageal squamous cell carcinoma[J]. Discov Med，2014，17（94）：169-178.
[6] DANSRANJAVIN T，WAGENLEHNER F，GATTENLOEHNER S，et al. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma[J]. Prostate，2012，72（14）：1550-1558.
[7] FAN C，WANG W，JIN J，et al. RASSF10 is epigenetically inactivated and suppresses cell proliferation and induces cell apoptosis by activating the p53 signalling pathway in papillary thyroid carcinoma cancer[J]. Cell Physiol Biochem，2017，41（3）：1229-1239.
[8] JIN Y，CAO B，ZHANG M，et al. RASSF10 suppresses hepatocellular carcinoma growth by activating P53 signaling and methylation of RASSF10 is a docetaxel resistant marker[J]. Genes Cancer，2015，6（5-6）：231-240.
[9] HAN X，DONG Q，WU J，et al. RASSF10 suppresses lung cancer proliferation and invasion by decreasing the level of phosphorylated LRP6[J]. Mol Carcinog，2019 ，58（7）：1168-1180.
[10] PAN Y，LIU G，ZHOU F，et al. DNA methylation profiles in cancer diagnosis and therapeutics[J]. Clin Exp Med，2018，18（1）：1-14.
[11] SAGHAFINIA S，MINA M，RIGGI N，et al. Pan-cancer landscape of aberrant DNA methylation across human tumors[J]. Cell Rep，2018， 25（4）：1066-1080.
[12] SEOIGHE C，TOSH N J，GREALLY J M. DNA methylation haplotypes as cancer markers[J]. Nat Genet，2018，50（8）：1062-1063.
[13] WANG F，FENG Y，LI P，et al. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma[J]. Oncotarget，2016，7（4）：4279-4297.
[14] GUO J，YANG Y，YANG Y，et al. RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel[J]. Oncotarget，2015，6（6）：4202-4213.
[15] JIANG C，KONG Z，LIU S，et al. Fusion radiomics features from conventional MRI predict MGMT promoter methylation status in lower grade gliomas[J]. Eur J Radiol，2019，121：108714.
[16] WANG F，LI P，FENG Y，et al. Low expression of RASSF10 is associated with poor survival in patients with colorectal cancer[J]. Hum Pathol，2017，62：108-114.
[17] DENG J，LIANG H，YING G，et al. Methylation of ras association domain protein 10（RASSF10） promoter negative association with the survival of gastric cancer[J]. Am J Cancer Res，2014，4（6）：916-923.
[18] HU Y，MA P，FENG Y，et al. Predictive value of the serum RASSF10 promoter methylation status in gastric cancer[J]. J Int Med Res，2019，47（7）：2890-2900.
[19] LIU Y，ZHU X，ZHANG W，et al. RASSF10 exhibits tumor suppressing potential involving tumor proliferation，metastasis and epithelial mesenchymal transition in esophageal squamous cell carcinoma[J]. Oncol Rep，2022，47（4）：80.

相似文献/References:

[1]梁绍平,王华庆.盐酸埃克替尼治疗晚期非小细胞肺癌的临床疗效观察[J].天津医科大学学报,2015,21(03):51.
　LIANG Shao-ping,WANG Hua-qing.Clinical observation of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer[J].Journal of Tianjin Medical University,2015,21(05):51.
[2]梁绍平,王华庆.盐酸埃克替尼治疗晚期非小细胞肺癌的临床疗效观察[J].天津医科大学学报,2015,21(01):51.
　LIANG Shao-ping WANG Hua-qing.Clinical observation of icotinib hydrochloride in the treatment of advanced non-small cell lung cancer[J].Journal of Tianjin Medical University,2015,21(05):51.
[3]李晶鑫,许芳秀,王玉,等.NFAT2在非小细胞肺癌中的表达及预后关联研究[J].天津医科大学学报,2016,22(05):417.
　LI Jing-xin,XU Fang-xiu,WANG Yu,et al.Relationship between expression of NFAT2 and survival prognosis in? non-small cell lung cancer[J].Journal of Tianjin Medical University,2016,22(05):417.
[4]李晶鑫,许芳秀,王玉,等.NFAT2在非小细胞肺癌中的表达及预后关联研究[J].天津医科大学学报,2016,22(05):417.
　LI Jing-xin,XU Fang-xiu,WANG Yu,et al.Relationship between expression of NFAT2 and survival prognosis in? non-small cell lung cancer[J].Journal of Tianjin Medical University,2016,22(05):417.
[5]黄晓莹.MRI与CT在非小细胞肺癌淋巴结转移诊断中的应用价值比较[J].天津医科大学学报,2017,23(06):542.
　HUANG Xiao-ying.Application value of MRI and CT in the diagnosis of lymph node metastasis of non-small cell lung cancer[J].Journal of Tianjin Medical University,2017,23(05):542.
[6]高会霞,王 彬,方 黎,等.3DCRT联合化疗对晚期NSCLC患者近期疗效及血清肿瘤标记物的影响[J].天津医科大学学报,2019,25(05):507.
[7]王红军,贾金广,朱婉凌,等.CXCL-14在非小细胞肺癌中的表达水平及临床意义[J].天津医科大学学报,2021,27(02):112.
　WANG Hong-jun,JIA Jin-guang,ZHU Wan-ling,et al.The expression level and clinical significance of CXCL-14 in non-small cell lung cancer[J].Journal of Tianjin Medical University,2021,27(05):112.
[8]张萌,孟昭婷,张翠翠,等.Super-ARMS法检测EGFR突变在NSCLC的临床应用[J].天津医科大学学报,2021,27(02):185.
　ZHANG Meng,MENG Zhao-ting,ZHANG Cui-cui,et al.Clinical application of EGFR mutation in NSCLC detect by the way of Super-arms[J].Journal of Tianjin Medical University,2021,27(05):185.
[9]严一杰,张军,王硕,等.125I粒子植入的靶区勾画对一线治疗后局部进展的非小细胞肺癌治疗效果影响[J].天津医科大学学报,2021,27(06):586.
　YAN Yi-jie,ZHANG Jun,WANG Shuo,et al.Effect of target delineation of 125I seed implantation on the treatment of locally advanced non-small cell lung cancer after first-line therapy[J].Journal of Tianjin Medical University,2021,27(05):586.
[10]陈嫱,英硕,李冠华,等.非小细胞肺癌M1期患者的危险、预后因素和转移特征：一项基于SEER数据库的研究[J].天津医科大学学报,2022,28(01):27.
　CHEN Qiang,YING Shuo,LI Guan-hua,et al.The risk，prognostic factors and metastatic features for patients with M1 stage of non-small cell lung cancer: a SEER-based study[J].Journal of Tianjin Medical University,2022,28(05):27.

备注/Memo

备注/Memo:

基金项目 国家自然科学基金（81472183）；天津市自然科学基金（18JCYBJC91600）；天津市医学重点学科（专科）建设项目（TJYXZDXK- 010A）
作者简介 张静怡（1987-），女，主治医师，硕士在读，肿瘤学；通信作者：赵伟鹏，E-mail：zhaoweipeng@tjmuch.com。

常用功能

更新日期/Last Update: 2024-09-20